Effects of Tirofiban on hemostatic activation and inflammatory response during cardiopulmonary bypass

American Journal of Cardiology

Volumn 91, Issue 3, 2003, Pages 346-347

  Koster, Andreas ^a,b,c,d   Chew, Derek P ^a,b,c,d   Kuebler, Wolfgang ^a,b,c,d   Habazettl, Helmut ^a,b,c,d   Bauer, Matthias ^a,b,c,d   Hausmann, Harald ^a,b,c,d   Hetzer, Roland ^a,b,c,d   Kuppe, Herman ^a,b,c,d   Hamm, Christian W ^a,b,c,d  

^a DEUTSCHES HERZZENTRUM BERLIN   (Germany)

^b FLINDERS MEDICAL CENTRE   (Australia)

^c FREIE UNIVERSITÄT BERLIN   (Germany)

^d KERCKHOFF HEART CENTER   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTITHROMBOCYTIC AGENT; FRESH FROZEN PLASMA; HEPARIN; PROTAMINE; TIROFIBAN; WARFARIN;

ADULT; AGED; ANTICOAGULATION; ARTICLE; BODY TEMPERATURE; BOLUS INJECTION; CARDIOPULMONARY BYPASS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; ERYTHROCYTE TRANSFUSION; FEMALE; HEMOSTASIS; HUMAN; INFLAMMATION; INFUSION; MALE; PLASMA TRANSFUSION; PREOPERATIVE TREATMENT; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; THROMBOCYTE COUNT; TREATMENT OUTCOME;

EID: 0037310859     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-9149(02)03167-3     Document Type: Article

References (5)

1. Asimakopoulos G. Systemic inflammtion and cardiac surgery an update. Perfusion. 16:2001;353-360.
2. Kupatt C.H., Habazettl H., Hanusch P., Wichels R., Hahnel D., Becker B.F., Boekstegers P. c7E3Fab reduces postischemic leukocyte-thrombocyte interaction mediated by fibrinogen. Implications for myocardial reperfusion injury. Arterioscler Thromb Vasc Biol. 20:2000;2226-2232.
3. Raymond P.D., Marsh N.A. Alterations to haemostasis following cardiopulmonary bypass and the relationship of these changes to neurocognitive morbidity. Blood Coagul Fibrinolysis. 12:2001;601-618.
4. Liuzzo G., Buffon A., Biasucci L.M., Biasucci L.M., Gallimore J.R., Caliguri G., Vitelli A., Altamira S., Ciliberto G., Rebuzi A.G., et al. Enhanced inflammatory response to coronary angioplasty in patients with severe unstable angina. Circulation. 98:1998;2370-2376.
5. Lincoff A.M., Kereiakes D.J., Mascelli M.A., Deckelbaum L.I., Barnathan E.S., Patel K.K., Frederik B., Nakada M.T., Topol E.J. Abciximab suppresses the rise of levels of circulating inflammatory markers after percutaneous coronary revascularization. Circulation. 104:2001;163-167.